GLP-1 diet study: what happens when you eat on ozempic?
NCT ID NCT07001553
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how people change their eating habits after starting GLP-1 drugs like Ozempic or Mounjaro for weight or diabetes. Researchers tracked 37 adults using dietary records and questionnaires to see if it's feasible to study diet changes this way. The goal was to understand recruitment and retention, not to test the drugs themselves.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GLP-1 agonist (e.g., Ozempic, Trulicity, Mounjaro, Saxenda)
- What this could lead to
- If successful, this could help doctors understand how diet changes with these medications, leading to better dietary advice for patients.
- What could go wrong
- This is a small, completed feasibility study with only 37 participants, so results may not apply broadly. It only observed dietary patterns, not treatment effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
37 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals living in Australia who are intending to commence a GLP-1 prescription
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18+ years old * Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months * The primary reason for commencing the medication will be for diabetes or weight management * Willing to participate in dietary recall and questionnaires Exclusion Criteria: * Aged under 18 years, * used a GLP-1 agonist medication in the previous 6 months, * unwilling or unable to provide dietary recalls * non-English speaking.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Australian Catholic University
Fitzroy, Victoria, 3065, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The acute effects of an endurance exercise bout the gut microbiome and gut-derived metabolome in Women's distinct fitness and body mass indexes
- Pilot study to evaluate the effect of nicotinamide riboside on immune activation in psoriasis
- The feasibility of electrical impedance tomography to guide non-invasive respiratory interventions in chronic respiratory disease
- Can a new injection help tackle obesity? a trial puts it to the test
- Does a Mother's weight change the chemistry of her breast milk?
- Can diverse tissue samples unlock Obesity's secrets?